BERKELEY, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, the Company’s Senior Vice President, Research and Development & Chief Medical Officer, is scheduled to present at the Cowen and Company Health Care Conference on Monday, March 7, 2016 at 2:40 p.m. ET.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 30 days following the presentation.
About XOMA Corporation
XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major impact on the treatment of hyperinsulinism. The Company recently initiated Phase 2 development activities for XOMA 358 in patients with congenital hyperinsulinism. For more information, visit www.xoma.com.
Company and Investor Contact: Ashleigh Barreto 510-204-7482 firstname.lastname@example.org Juliane Snowden The Oratorium Group, LLC email@example.com Media Contact: Ryan Flinn W2O Group 415-946-1059 firstname.lastname@example.org